< Back to previous page
Researcher
Chantal Mathieu
- Disciplines: Other clinical sciences not elsewhere classified
Affiliations
1 - 1 of 1
- Clinical and Experimental Endocrinology (Division)
Member
From 1 Oct 1999 → Today
Infrastructure
1 - 1 of 1
Projects
1 - 10 of 91
- Targeting neutrophil plasticity to improve anti-CD3 immunotherapy outcomes in type 1 diabetesFrom 21 Aug 2026 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Identification of novel pathways regulating beta cell demise in Type 1 diabetes.From 26 May 2026 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- MAPS-T1D: Multi-omics Analysis of the Pancreas, Spatially resolved, in childhood and adult-onset Type 1 DiabetesFrom 1 Oct 2025 → TodayFunding: BOF - postdoctoral mandates
- Investigating natural history and therapeutic strategies across different stages of type 1 diabetes using innovative technologies.From 13 Sep 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- How Can Multiphase Optimization Strategy (MOST), enriched by perspectives of social determinants of health and lived experience with T1D, optimally inform design and implementation of early detection of T1D? – The case of EDENT1FI general population earlyFrom 12 Jun 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Age-related heterogeneity in response to disease-modifying therapies in new-onset type 1 diabetesFrom 1 Jan 2025 → TodayFunding: FWO research project (including WEAVE projects)
- Continued provision of an affordable medium-parametric cell analysis solution at the KU Leuven Flow Cytometry core facilityFrom 1 Jan 2025 → 31 Dec 2025Funding: Own budget, for example: patrimony, inscription fees, gifts
- Continued provision of an affordable medium-parametric cell analysis solution at the KU Leuven Flow Cytometry core facilityFrom 1 Jan 2025 → 31 Dec 2025Funding: BOF - scientific equipment program
- Personalized precision medicine for the prevention and reversal of type 1 diabetes: a stepwise approachFrom 1 Oct 2024 → TodayFunding: BOF - various, BOF - projects
- Neutrophils and their role in type 1 diabetesFrom 10 Sep 2024 → 1 Sep 2025Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 746
- Simplified Switching to Once-Weekly Insulin Icodec Without an Initial One-Time Additional Dose Versus Once-Daily Insulin Glargine U100 in Basal Insulin-Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial(2026)Published in: Diabetes, Obesity & MetabolismISSN: 1462-8902Issue: 9Volume: 28
- Antigen-specific tolerance therapies in type 1 diabetes: Disease-specific promises meet stage-specific challenges(2026)Published in: Autoimmunity ReviewsISSN: 1568-9972Issue: 9Volume: 25
- CGM Metrics and the Risk of Pregnancy Complications in Type 1 Diabetes: A Secondary Exploratory Analysis of the CRISTAL Trial(2026)Published in: Diabetes Technology & TherapeuticsISSN: 1520-9156
- Citrullination and Deamidation in Type 1 Diabetes: Linking Beta Cell Stress to Neoantigen-Driven Autoimmunity(2026)Published in: Immunological ReviewsISSN: 0105-2896Issue: 1Volume: 341
- GLP1-E2 therapy delays autoimmune diabetes in late-stage prediabetic NOD mice and potentiates low-dose anti-CD3 therapy for enhanced disease protection(2026)Published in: DiabetologiaISSN: 0012-186XIssue: 8Volume: 69Pages: 2307 - 2322
- Advancing Early-Stage Type 1 Diabetes Care: Future Focused Pathways for Identification, Screening, Diagnosis, and Monitoring(2026)Published in: Diabetes, Obesity & MetabolismISSN: 1462-8902Issue: 8Volume: 28
- Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study(2026)Published in: The Lancet Diabetes & EndocrinologyISSN: 2213-8587Issue: 8Volume: 14Pages: 649 - 661
- Diabetes Care in 2050: A Human-Centered Road Map From Time in Range to Time in Happiness.(2026)Published in: Diabetes CareISSN: 0149-5992Pages: dci260059
- Psychosocial implications, acceptability and ethics of screening for paediatric type 1 diabetes: a systematic review and mixed methods evidence synthesis(2026)Published in: DiabetologiaISSN: 0012-186XIssue: 7Volume: 69Pages: 1759 - 1781
- Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes(2026)Published in: Diabetes Technology & TherapeuticsISSN: 1520-9156Issue: 7Volume: 28Pages: 717 - 728
Patents
1 - 8 of 8
- Methods And Compositions For Treating Type 1 Diabetes Comprising Teplizumab And Verapamil
- Biomarkers for diabetes therapy
- BIOMARKERS FOR DIABETES THERAPY
- Biomarkers for diabetes therapy
- Improved methods for pancreatic islet transplantation
- Citrullinated peptides for diagnosis or treatment of diabetes
- Improved methods for pancreatic islet transplantation
- RESISTANCE TO OXIDATIVE STRESS